Clinical trial NCT00365053 (phase 2, status: completed)
Conditions: advanced malignant mesothelioma, epithelial mesothelioma, recurrent malignant mesothelioma, sarcomatous mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: belinostat
SMILES: ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed malignant pleural mesothelioma (MPM) of any
             of the following subtypes:

               -  Epithelial

               -  Sarcomatoid

               -  Mixed

          -  Have received only 1 prior systemic chemotherapy regimen for advanced mesothelioma

               -  Prior intrapleural cytotoxic agents (including bleomycin) not considered systemic
                  chemotherapy

               -  Patients who are not candidates for combination chemotherapy are eligible even if
                  they have not received prior chemotherapy

          -  Unresectable disease

          -  Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by
             conventional techniques OR >= 10 mm by spiral CT scan

               -  The sole site of measurable disease must not be located within the radiotherapy
                  port

          -  No known brain metastases

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

          -  Life expectancy > 3 months

          -  WBC >= 3,000/mm^3

          -  Absolute neutrophil count >= 1,500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Bilirubin normal

          -  AST/ALT =< 2.5 times upper limit of normal

          -  Creatinine normal OR creatinine clearance >= 50 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-barrier contraception for 1 week before,
             during, and for >= 2 weeks after completion of study treatment

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to PXD101

          -  No symptomatic congestive heart failure

          -  No congestive heart failure related to primary cardiac disease

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No condition requiring anti-arrhythmic therapy

          -  No uncontrolled hypertension

          -  No myocardial infarction within the past 6 months

          -  No ischemic or severe valvular heart disease

          -  No ongoing or active infection

          -  No marked baseline prolongation of QT/QTc interval

          -  No repeated QTc interval > 500 msec

          -  No long QT syndrome

          -  No other significant cardiovascular disease

          -  No other uncontrolled intercurrent illness

          -  No psychiatric illness or social situation that would preclude study compliance

          -  Recovered from prior therapy

          -  No prior valproic acid or other known histone deacetylase (HDAC) inhibitor

          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

          -  More than 3 weeks since prior radiation therapy

          -  No concurrent medication that may cause torsade de pointes

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational agents

          -  No other concurrent anticancer agents or therapies